Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, Masuda H, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Kosaka N, Tajima K, Masuda N. Yoshinami T, et al. Among authors: masuda n. Breast Cancer. 2024 Apr 20. doi: 10.1007/s12282-024-01575-5. Online ahead of print. Breast Cancer. 2024. PMID: 38642245
Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Masuda N, Taguchi T, Nakayama T, Shiba E, Watatani M, Kurebayashi J, Takatsuka Y, Sakamoto J, Noguchi S; Kinki Breast Cancer Study Group (KBCSG). Masuda N, et al. Cancer Chemother Pharmacol. 2008 May;61(6):989-95. doi: 10.1007/s00280-007-0555-z. Epub 2007 Jul 20. Cancer Chemother Pharmacol. 2008. PMID: 17641893 Clinical Trial.
[Mohs paste for unresectable local lesion of breast cancer].
Ogawa H, Masuda N, Masuda H, Yamamura J, Nakamori S, Tsujinaka T, Yoshitatu S, Nakashotani N, Ueno H, Matsuyama K, Hattori Y, Todaka K, Nishimura A. Ogawa H, et al. Among authors: masuda h, masuda n. Gan To Kagaku Ryoho. 2008 Sep;35(9):1531-4. Gan To Kagaku Ryoho. 2008. PMID: 18799906 Japanese.
Predictive factors for anthracycline-based chemotherapy for human breast cancer.
Miyoshi Y, Kurosumi M, Kurebayashi J, Matsuura N, Takahashi M, Tokunaga E, Egawa C, Masuda N, Kono S, Morimoto K, Kim SJ, Okishiro M, Yanagisawa T, Ueda S, Taguchi T, Tamaki Y, Noguchi S. Miyoshi Y, et al. Among authors: masuda n. Breast Cancer. 2010 Apr;17(2):103-9. doi: 10.1007/s12282-009-0152-6. Epub 2009 Aug 6. Breast Cancer. 2010. PMID: 19657712 Review.
Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Taguchi T, Nakayama T, Masuda N, Yoshidome K, Akagi K, Nishida Y, Yoshikawa Y, Ogino N, Abe C, Sakamoto J, Noguchi S; Kinki Breast Cancer Study Group. Taguchi T, et al. Among authors: masuda n. Chemotherapy. 2010;56(2):166-70. doi: 10.1159/000313531. Epub 2010 Apr 21. Chemotherapy. 2010. PMID: 20407245 Clinical Trial.
Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population.
Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S, Nakayama T, Kashiwaba M, Kamigaki S, Kuroi K; Japan Breast Cancer Research Group-Translational Research Group. Toi M, et al. Among authors: masuda n. Cancer. 2010 Jul 1;116(13):3112-8. doi: 10.1002/cncr.25206. Cancer. 2010. PMID: 20564629 Free article.
1,176 results